In a phase I clinical trial report of satri-cel (claudin 18.2-directed CAR T-cell therapy), three patients with advanced gastric cancer and peritoneal metastasis achieved durable peritoneal disease control. The report (NCT03874897) highlights confirmed high claudin 18.2 expression and clinical and radiologic benefit in all treated patients. The cases also show a disconnect between peripheral CAR T-cell clearance and local tissue persistence, with circulating cells becoming nearly undetectable around day 30 while peritoneal responses continued. For peritoneal metastasis—where prognosis is poor and treatment options are limited—this type of compartment-specific activity is clinically relevant. For cell therapy developers, the findings reinforce the need to measure both systemic kinetics and tumor-site persistence when evaluating efficacy. For oncologists, the results provide early support for claudin 18.2 as a target that may translate beyond mucosal primary lesions to peritoneal disease. The durability reported in these small cohorts is hypothesis-generating; larger, controlled studies will be needed to confirm response rates, safety, and reproducibility across broader claudin 18.2-positive populations.